Pharmacoeconomics of Angiotensin II Antagonists in Type 2 Diabetic Patients with Nephropathy Cornelis BoersmaJarir AtthobariMaarten J. Postma Leading Article 27 November 2012 Pages: 523 - 535
Healthcare Rationing in Spain Rosa Rodríguez-MonguióFernando Antoñanzas Villar Review Article 27 November 2012 Pages: 537 - 548
The Impact of Losartan on the Lifetime Incidence of End-Stage Renal Disease and Costs in Patients with Type 2 Diabetes and Nephropathy George W. CaridesShahnaz ShahinfarBarry M. Brenner Original Research Article 27 November 2012 Pages: 549 - 558
The Effects of Type 1 Diabetes and its Long-Term Complications on Physical and Mental Health Status Jarmo HahlHelena HämäläinenOlli Simell Original Research Article 27 November 2012 Pages: 559 - 569
Cost Effectiveness of Enoxaparin as Prophylaxis against Venous Thromboembolic Complications in Acutely Ill Medical Inpatients Peter K. SchädlichMichael KentschEduard Huppertz Original Research Article 27 November 2012 Pages: 571 - 591
Dalteparin versus Warfarin for the Prevention of Recurrent Venous Thromboembolic Events in Cancer Patients George DranitsarisMark VincentMark Crowther Original Research Article 27 November 2012 Pages: 593 - 607
Is the Childhood Asthma Questionnaire a Good Measure of Health-Related Quality of Life of Asthmatic Children in Asia? Lee-Yee ChongOh-Moh ChayLi Shu-Chuen Original Research Article 27 November 2012 Pages: 609 - 621
Modelling the Cost Effectiveness of Cholinesterase Inhibitors in the Management of Mild to Moderately Severe Alzheimer’s Disease Nick BosanquetAndrew Yeates Correspondence 27 November 2012 Pages: 623 - 625
The Authors’ Reply Colin GreenJoanna PicotAndrew Clegg Correspondence 27 November 2012 Pages: 625 - 626